Abstract | AIMS: METHODS: A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo. Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis. Mean differences in HbA1c relative to placebo or each other and probability rankings were estimated. RESULTS: Estimated mean differences in HbA1c versus placebo were -1.15% (95% CrI: -1.31 to -1.00) for ExQW, -1.01% (95% CrI: -1.18 to -0.85) for liraglutide 1.2 mg, and -1.18% (95% CrI: -1.32 to -1.04) for liraglutide 1.8 mg. HbA1c differences for ExQW versus liraglutide 1.2 mg and 1.8 mg were -0.14% (95% CrI: -0.34 to 0.06) and 0.03% (95% CrI: -0.14 to 0.18), respectively. The estimated mean difference in HbA1c between liraglutide 1.2 mg and 1.8 mg was 0.17% (95% CrI: 0.02-0.30). Results were consistent when adjusted for background antihyperglycaemic medications and diabetes duration. CONCLUSIONS: This network meta-analysis did not identify meaningful differences in HbA1c lowering between ExQW and both liraglutide doses, suggesting that these GLP-1 RAs have similar glycaemic effects.
|
Authors | D A Scott, K S Boye, L Timlin, J F Clark, J H Best |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 15
Issue 3
Pg. 213-23
(Mar 2013)
ISSN: 1463-1326 [Electronic] England |
PMID | 22958381
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Copyright | © 2012 Blackwell Publishing Ltd. |
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin, Long-Acting
- Peptides
- Venoms
- hemoglobin A1c protein, human
- Insulin Glargine
- Liraglutide
- Glucagon-Like Peptide 1
- Exenatide
|
Topics |
- Blood Glucose
(drug effects, metabolism)
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Drug Administration Schedule
- Exenatide
- Female
- Glucagon-Like Peptide 1
(administration & dosage, analogs & derivatives, pharmacology)
- Glycated Hemoglobin
(drug effects, metabolism)
- Humans
- Hypoglycemic Agents
(administration & dosage, pharmacology)
- Insulin Glargine
- Insulin, Long-Acting
(administration & dosage, pharmacology)
- Liraglutide
- Male
- Peptides
(administration & dosage, pharmacology)
- Treatment Outcome
- Venoms
(administration & dosage, pharmacology)
|